Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Cosmetic – antiperspirant – dentifrice
Reexamination Certificate
2007-06-19
2007-06-19
Tran, Susan (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Cosmetic, antiperspirant, dentifrice
C424S440000, C424S451000, C424S464000, C514S152000
Reexamination Certificate
active
11061866
ABSTRACT:
A method of treating rosacea in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat rosacea, but has substantially no antibiotic activity.
REFERENCES:
patent: 5122519 (1992-06-01), Ritter
patent: 5157046 (1992-10-01), Van Wauwe et al.
patent: 5260292 (1993-11-01), Robinson et al.
patent: 5505949 (1996-04-01), Benitez
patent: 5674539 (1997-10-01), Tomas et al.
patent: 5827840 (1998-10-01), Ramamurthy et al.
patent: 5908838 (1999-06-01), Gans
patent: 5998390 (1999-12-01), Ramamurthy et al.
patent: 6015803 (2000-01-01), Wirostko
patent: 6133310 (2000-10-01), Parks
patent: 6455583 (2002-09-01), Pflugfelder et al.
patent: 6664287 (2003-12-01), Avery et al.
patent: 6673843 (2004-01-01), Arbiser
patent: 7008631 (2006-03-01), Ashley
patent: 7014858 (2006-03-01), Ashley
patent: 2003/0082120 (2003-05-01), Milstein
patent: 2003/0139380 (2003-07-01), Ashley
patent: 0 410 099 (1991-01-01), None
patent: 02006437 (1990-01-01), None
patent: WO 83/00628 (1983-03-01), None
patent: WO 99/58131 (1999-11-01), None
Wong et al., “Oral ibuprofen and tetracycline for the treatment of acne vulgaris”, Journal of American Academy of Dermatology, pp. 1076-1081 (1984).
Akamatsu, et al. “Effect of Keigai-Rengyo-To, a Japanese Kampo Medicine, on Neutorphil Functions: a Possible Mechanism of Action of Keigai-Rengyo-To in Acne,”The Journal of International Medical Research, 25: 255-265 (1997).
Baer, et al., “High-Dose Tetracycline Therapy in Severe Acne,”Arch Dermatol, 112:479-481 (Apr. 1976).
Cheryl Guttman, “Emerging resistance changes face to antibiotic therapy for acne,”Dermatology Times, Jan. 2001, p. 22.
Hirohiko Akamatsu, Maki Asada, Jinro Komura, Yasuo Asada, and Yukie Niwa, “Effect of Doxycycline on the Generation of Reactive Oxygen Species: A Possible Mechanism of Action of Acne Therapy with Doxycycline,”Acta Derm Venereol(Stockh) 72:178-178 (1992).
Bodokh, Y. Jacomet, J. Ph. Lacour and J.P. Ortonne, “Minocycline Induces an Increase in the Number of Excreting Pilosebaceous Follicles in Acne Vulgaris,”Acta Derm Venereol(Stockh), 77:255-259 (1997).
W. J. Cunliffe, M.D., F.R.C.P., “Evolution of a Strategy for the Treatment of Acne,”J Am Acad Dermatol, 16:591-9 (1987).
E. Anne Eady, Eileen Ingham, Christina E. Walters, Jonathan H. Cove, and William J. Cunliffe, “Modulation of Comedonal Levels of Interleukin-1 in Acne Patients Treated with Tetracyclines,”J. Invest Dermatol, 101:86-91 (1993).
Boni E. Elewski, M.D., Beth A.J. Lamb, W. Mitchell Sams, Jr., M.D., and W. Ray Gammon, M.D., “In Vivo Suppression of Neutrophil Chemotaxis by Systemically and Topically Administered Tetracycline,”J Am Acad Dermatol, 8:807-812 (1983).
Nancy B. Esterly, M.D., Nancy L. Furey, M.D., and Lillian E. Flanagan, B.S., “The Effect of Antimicrobiol Agents on Leukocyte Chemotaxis,”The Journal of Investigative Dermatology, 70(1):51-55 (1978).
Sainte-Marie, I. Tenaud, O. Jumbou and B. Dréno, “Minocycline Modulation of Alpha-MSH Production by Keratinocytes In vitro,”Acta Derm Venereol 79:265-267 (1999).
Hoshiki Miyachi, M.D., Akira Yoshioka, M.D., Sadao Imamura, M.D., and Yukie Niwa, M.D., “Effect of Antibiotics on the Generation of Reactive Oxygen Species,”J Invest Dermatol, 86(4):449-453 (1986).
Gerd Plewig, M.D., and Erwin Schöpf, M.D., “Anti-Inflammatory Effects of Antimicrobial Agents: An In Vivo Study,”The Journal of Investigative Dermatology, 65:532-536 (1975).
M. Toyoda and M. Morohashi, “An Overview of Topical Antibiotics for Acne Treatment,”Dermatology, 196:130-134 (1998).
Sheila E. Unkles, and Curtis G. Gemmell, “Effect of Clindamycin, Erythromycin, Lincomycin, and Tetracycline on Growth and Extracellular Lipase Production by Propionibacteria In Vitro,”Antimicrobial Agents and Chemotherapy, 21:39-43 (1982).
G.F. Webster, K.J. McGinley, and J.J. Leyden, “Inhibition of Lipase Production inPropionibacterium acnesby Sub-Minimal-Inhibitory Concentration of Tetracycline and Erythromycin,”British Journal of Dermatology, 104:453-457 (1981).
Guy F. Webster, M.D., Ph. D., Susan M. Toso, M.S., and Lutz Hegemann, M.D., Ph.D., “Inhibition of a Model of In Vitro Granuloma Formation by Tetracyclines and Ciprofloxacin,”Arch Dermatol., 130:748-752 (1994).
Reynold C. Wong, M.D., Sewon Kang, M.P.H., Jan L. Heezen, L.P.N., John J. Voorhees, M.D., and Charles N. Ellis, M.D., “Oral Ibuprofen and Tetracycline for the Treatment of Acne Vulgaris,”J Am Acad Dermatol, 11:1076-1081 (1984).
Kenneth S. Kornman and Edward H. Karl, “The Effect of Long-Term Low-Dose Tetracycline Therapy on the Subgingival Microflora in Refractory Adult Periodontitis,”J. Periodontol., 53(10):604-610 (Oct. 1982).
Bikowski, J.B., “Treatment of rosacea with doxycycline monohydrate,” Curtis. Aug. 2000, 66(2):149-152.
Jimenez-Acosta, “Response to tetracycline of telangiectasias in male hemophiliac with human immunodeficiency virus infection,” J. Am. Acad. Dermatol. Aug. 1988, 19(2 Pt. 1):369-379.
Torresani, C., “Clarithromycin versus doxycycline in the treatment of rosacea,” Int. J. Clin. Dermatol. Dec. 1997, 36(12):942-946.
McClellan, K.J., “Topical Metronidazole. A review of its use in rosaea,” Am. J. Clin. Dermatol. May-Jun. 2000, 1(3):191-199.
Quarterman, M.J., “Ocular Rosacea. Signs, symptoms and tear studies before and after treatment with doxycycline,” Arch. Dermatol. Jan. 1997, 133(1):49-54.
Stedman's Medical Dictionary 27thEdition.
Akamatsu, et al. “Effect of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism.”Arch Dermatol Res 283:524-528 (1991).
Bikowski, et al. “Treatment of rosacea with doxycycline monohydrate”Cutis, 66:149-152 (Aug. 2000).
Golub, et al. “Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs”Critical Reviews in Oral Biology and Medicine, 2(2):297-322 (1991).
Illig “Positive side effects of antibiotic and antimicrobial substances in therapy”Infection 7(Suppl. 6): S 584-588 (1979) (English translation. Original document in German.).
Knight, et al. “A follow-up of tetracycline-treated rosacea”British Journal of Dermatology 93:577-580 (1975).
Marks, et al. “Comparative effectiveness of tetracycline and ampicillin in rosacea”The Lancet, 1049-1052 (Nov. 13, 1971).
Millar, et al. “A general practice study investigating the effect of minocycline (Minocin) 50 mg bd for 12 weeks in the treatment of acne vulgaris”The British Journal of Clinical Practice41(8):882-886 (Aug. 1987).
Plewig, et al.Acne: Morphogenesis and Treatment, Springer-Verlag 297-301 (1975).
Webster, et al. “Suppression of Polymorphonuclear Leukocyte Chemotactic Factor Production inPropionibacterium acnesby Subminimal Inhibitory Concentrations of Tetracycline, Amplicillin, Minocycline, and Erythromycin”Antimicrobial Agents and Chemotherapy21(5):770-772 (1982).
Skidmore et al., “Effects of Subantimicrobial-Dose Doxycycline in the Treatment of Moderate Acne,”Archives of Dermatology139:459-464 (Apr. 2003), XP009047590.
CollaGenex Pharmaceuticals, Inc.
Hoffmann & Baron , LLP
Tran Susan
LandOfFree
Methods of treating rosacea does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating rosacea, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating rosacea will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3872601